The role of standard-dose cytarabine in children with acute promyelocytic leukemia: a single-center experience.

Abstract

BACKGROUND:

There are very limited data reported about the role of cytarabine (Ara-C) in childhood acute promyelocytic leukemia (APL). We review the clinical course and treatment outcome of APL and explore the role of standard-dose Ara-C for children.

PROCEDURE:

Between January 1999 and December 2008, 36 children (<14 y) with newly diagnosed APL were included.

RESULTS:

The overall complete remission rate was 97.2% (35/36). Two patients were lost to follow-up after induction. Two groups of patients were identified according to different consolidation chemotherapy regimens. Seventeen patients were given polychemotherapy in combination with standard-dose Ara-C (group I), 16 patients were given daunorubicin alone (group II). Although the 5-year estimate of disease-free survival between groups I and II had no statistically significant difference (P = 0.614), there was a 12% higher disease-free survival rate for group I.

CONCLUSION:

Standard-dose Ara-C might play some role in the consolidation treatment of children suffering from APL.

• Authors: Li Zhang, Xiaofan Zhu, Xiaojuan Chen, Yumei Chen, Yao Zou
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 33 Issue 2 Pg. e46-50 (Mar 2011) ISSN: 1536-3678 [Electronic] United States
• PMID: 21127433 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antimetabolites, Antineoplastic
• Cytarabine
• Tretinoin
• Mercaptopurine
• Methotrexate
• Daunorubicin

Topics

• Adolescent
• Antimetabolites, Antineoplastic (administration & dosage, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Child
• Child, Preschool
• Cytarabine (administration & dosage, therapeutic use)
• Daunorubicin (therapeutic use)
• Disease-Free Survival
• Female
• Humans
• Infant
• Kaplan-Meier Estimate
• Leukemia, Promyelocytic, Acute (drug therapy, mortality)
• Male
• Mercaptopurine (therapeutic use)
• Methotrexate (therapeutic use)
• Treatment Outcome
• Tretinoin (therapeutic use)